MDSpire - Summary
From the Journals

Molecular Test Doubles Detection of Bile Duct Cancer

According to recent research, a new molecular test could detect bile duct cancer with twice the sensitivity of the standard test, giving physicians a more accurate picture of a patient’s diagnosis. 

Share

A recent study led by Dr. Adam Slivka from the University of Pittsburgh introduces BiliSeq, a molecular test for diagnosing bile duct cancer more effectively than standard methods. BiliSeq demonstrates approximately 82% sensitivity in detecting cancer, compared to 44% with traditional pathology. The test has shown to significantly impact treatment decisions, offering personalized insights into patient care by identifying genetic mutations in challenging cases. It is particularly beneficial for patients with bile duct obstructions, providing crucial information for appropriate management.

Original Source(s)

Molecular Test Doubles Detection of Bile Duct Cancer

  • by The ASCO Post Staff

  • March 31, 2026

Related Content

New Histology Signal in Crohn’s

Distinct lymphoid structures identified in fibrostenosing Crohn’s specimens

  • March 26, 2026

  • 2 min
ESD with DiLumen IgE; Grasp and Final Cut

ESD can be especially challenging without traction.  In this video Dr. Molham Abdulsamad of Geisinger Health demonstrates how he can greatly extend retraction and broadly expose and dissect the last attachments at the end of the ESD procedure.

  • March 24, 2026

ESD with DiLumen IgE; Grasp, Lift and Cut 3

ESD can be especially challenging without traction.  In this video Dr. Molham Abdulsamad of Geisinger Health demonstrates that with Lumendi’s IgE Grasper he can regrasp and reposition traction during the procedure to maximize submucosal exposure during ESD.

  • March 24, 2026